A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
- To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in
order to confirm clinical value of SPM 962.
- To demonstrate the superiority of SPM 962 to placebo in terms of efficacy.
- To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.